Drug Profile
TDENV LAV
Alternative Names: Dengue vaccine live - GlaxoSmithKline; T-DEN F-19; T-DEN F17; TDENV-LAV F17; Tetravalent dengue live attenuated virus formulation 17; WRAIR Live Attenuated Tetravalent Dengue VaccineLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GlaxoSmithKline; Oswaldo Cruz Foundation; Walter Reed Army Institute of Research
- Class Dengue vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Dengue
Most Recent Events
- 05 Apr 2017 GlaxoSmithKline withdraws a phase I trial in Dengue (prevention) prior to enrolment in USA (NCT03110952)
- 18 Jun 2013 Discontinued - Phase-I/II for Dengue (prevention, in adults) in Thailand (SC)
- 18 Jun 2013 Discontinued - Phase-I/II for Dengue (prevention, in children) in Thailand (SC)